Your browser doesn't support javascript.
loading
Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial.
Wei, L-H; Su, Y-Y; Hu, Y-M; Li, R-C; Chen, W; Pan, Q-J; Zhang, X; Zhao, F-H; Zhao, Y-Q; Li, Q; Hong, Y; Zhao, C; Li, M-Q; Liu, W-Y; Li, C-H; Guo, D-P; Ke, L-D; Lin, B-Z; Lin, Z-J; Chen, S; Sheng, W; Zheng, Z-Z; Zhuang, S-J; Zhu, F-C; Pan, H-R; Li, Y-M; Huang, S-J; Zhang, J; Qiao, Y-L; Wu, T; Xia, N-S.
Afiliación
  • Wei LH; Peking University People's Hospital, Beijing, China.
  • Su YY; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Hu YM; Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing, Jiangsu, China.
  • Li RC; Guangxi Centre for Disease Control and Prevention, Nanning, Guangxi, China.
  • Chen W; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.
  • Pan QJ; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.
  • Zhang X; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.
  • Zhao FH; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.
  • Zhao YQ; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.
  • Li Q; Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, Guangdong, China.
  • Hong Y; The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
  • Zhao C; Peking University People's Hospital, Beijing, China.
  • Li MQ; Liuzhou Centre for Disease Control and Prevention, Liuzhou, Guangxi, China.
  • Liu WY; Funing Centre for Disease Control and Prevention, Funing, Jiangsu, China.
  • Li CH; Xinmi Maternal and Child Health Hospital, Xinmi, Henan, China.
  • Guo DP; Yangcheng Maternal and Child Health Hospital, Yangcheng, Shanxi, China.
  • Ke LD; Fengning Hospital of Traditional Chinese Medicine, Fengning, Hebei, China.
  • Lin BZ; Xiamen Innovax Biotech Company, Xiamen, Fujian, China.
  • Lin ZJ; Xiamen Innovax Biotech Company, Xiamen, Fujian, China.
  • Chen S; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Sheng W; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zheng ZZ; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zhuang SJ; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zhu FC; Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing, Jiangsu, China.
  • Pan HR; Xiamen Innovax Biotech Company, Xiamen, Fujian, China.
  • Li YM; Xiamen Innovax Biotech Company, Xiamen, Fujian, China.
  • Huang SJ; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Zhang J; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
  • Qiao YL; National Cancer Centre, National Centre for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China. Electronic address: qiaoy@cicams.ac.cn.
  • Wu T; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China. Electronic address:
  • Xia NS; The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Centre of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.
Clin Microbiol Infect ; 26(8): 1069-1075, 2020 Aug.
Article en En | MEDLINE | ID: mdl-31904566
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Anticuerpos Neutralizantes Tipo de estudio: Clinical_trials / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Middle aged País/Región como asunto: Asia Idioma: En Revista: Clin Microbiol Infect Asunto de la revista: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Anticuerpos Neutralizantes Tipo de estudio: Clinical_trials / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Middle aged País/Región como asunto: Asia Idioma: En Revista: Clin Microbiol Infect Asunto de la revista: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: China